Arcticzymes Technologies ASA operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Arcticzymes Technologies ASA with three other pharmaceutical manufacturers in Europe: Biocorp Production SA of FRANCE (2020 sales of 8.46 million Euros [US$10.25 million] ), Mithra Pharmaceuticals SA of BELGIUM (9.03 million Euros [US$10.95 million] of which 60% was Out-licensing), and Dbv Technologies which is based in FRANCE (9.83 million Euros [US$11.91 million] of which 100% was immunotherapy products).

Sales Analysis. Sales were up sharply during the first quarter of 2021 versus the previous year's first quarter. During the first quarter of 2021, sales at Arcticzymes Technologies ASA totalled NOK 40.45 million. This is an increase of 80.7% from the NOK 22.38 million in sales at the company during the first quarter of 2020. This was the largest same quarter increase in sales since the first quarter of 2015. During the year ended December of 2020, sales at Arcticzymes Technologies ASA were NOK 93.45 million (US$11.23 million). This is an increase of 21.0% versus 2019, when the company's sales were NOK 77.25 million. This was the third consecutive year of growth at Arcticzymes Technologies ASA. Sales of Enzymes saw an increase that was more than double the company's growth rate: sales were up 106.8% in 2020, from NOK 45.19 million to NOK 93.45 million.